HIV-1 Tat compositions

Details HIV-1 Tat compositions HIV-1 Tat compositions

1998-11-30

2010-06-29

Mondesi, Robert B (Department: 1648)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Amino acid sequence disclosed in whole or in part; or...

C424S184100, C424S185100, C424S186100, C424S187100, C424S208100, C536S023720, C435S069300

Reexamination Certificate

active

07744896

ABSTRACT:
The present invention refers to Tat as the active principle for a prophylactic and/or therapeutic vaccine against HIV infection, the progression towards AIDS and the development of tumors and other syndromes and symptoms in subjects infected by HIV. Tat is in biologically active form either as recombinant protein or peptide or as DNA. More particularly, the invention refers to a vaccine based on HIV-1 Tat as immunogen, inoculated as DNA and/or recombinant protein or as peptides, alone or in combination with other genes or viral gene products (Nef, Rev, Gag) or parts thereof, or in combination with various immuno modulant cytokines (IL-12, IL-15) or with the gene coding for an immuno modulant cytokine or part thereof. Tat, Nef, Rev, Gag and the immuno modulant cytokines are administrated both as a mixture of recombinant proteins, peptides or fusion proteins (Tat/Nef, Tat/Rev, Tat/Gag, Tat/IL-12, Tat/IL-15) or as plasmid DNA.

REFERENCES:
patent: 5646120 (1997-07-01), Sumner-Smith et al.
patent: 5652122 (1997-07-01), Frankel et al.
patent: WO9403596 (1994-02-01), None
patent: WO9415634 (1994-07-01), None
patent: WO9531999 (1995-11-01), None
patent: 87/02989 (1997-05-01), None
patent: WO9817309 (1998-04-01), None
Riffkin et al. “A single amino-acid change between the antigenically different extracellular serine proteases V2 and B2 fromDichelobacter nodosus”, Gene, vol. 167 (1995), pp. 279-283.
Abaza et al. “Effects of amino acid substitutions outside an antigenic site on protein binding to monoclonal antibodies of predetermined specificity obtained by peptide immunization”,Journal of Protein Chemistry, vol. 11, No. 5 (1992), pp. 433-444.
Cruse et al.Illustrated Dictionary of Immunology(Boca Raton, FL, CRC Press, Inc., 1995), p. 309. QR180.4.C78.
Paul,Fundamental Immunology, (Philadelphia & New York, Lippincott-Raven Publishers, 1993), pp. 250 and 1311-1312. QR181.F84.
Cafaro et al. “Control of SHIV 89.6P infection of cynomolgus monkeys by HIV 1 Tat protein vaccine” Nature Medicine, vol. 5, No. 6(Jun. 1999), pp. 643-650.
Feinberg et al. “AIDS vaccine models: Challenging challenge viruses” Nature Medicine, vol. 8, No. 3(Mar. 2002), pp. 207-210.
Chang et al. “HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region”, AIDS, vol. 11, No. 12 (Oct. 11, 1997), p. 1421-1431.
Chengalvala et al. “Enhanced immunogenicity of hepatitis B surface antigen by insertion of a helper T cell epitope from tetanus toxoid”, Vaccine, vol. 17, Nos. 9-10(Mar. 5, 1999) pp. 1035-1041.
Heiman et al. “HIV Vaccines: Where are we Going?” Nature Medicine Vaccine Supplement (May 1998) reproduced by the NIAID Division of AIDS at http://www.niaid.nih.gov/daids/vaccine/1998nature.htm.
Vogel, F.R., Powell, M.F., 1995. A compendium of vaccine adjuvants and excipients. In: Powell, M.F., Newman, M.J. (Eds.), Vaccine Design. The Subunit and Adjuvant Approach. Plenum, New York, pp. 1, 9, 10, 51, and 52.
Hengge et al. “Randomized, controlled phase II trial of subcutaneous interleukin-2 in combination with highly active antiretroviral therapy (HAART) in HIV patients”, AIDS, vol. 12, No. 17(Nov. 1998), pp. F225-F234.
Castignolles et al. “A new family of carriers (biovectors) enhances the immunogenicity of rabies antigens”, Vaccine, vol. 14, No. 14(Oct. 1996) pp. 1353-1360.
Ramshaw et al. “Enhanced antibody responses to antigens presented on autologous erythrocytes”, Journal of immunological methods, vol. 18, Nos. 3-4,(1977) pp. 251-255. Abstract Only.
Livingston et al. “The hepatitis B virus-specific CTL responses induced in humans by lipopeptide vaccination are comparable to those elicited by acute viral infection”, Journal of Immunology, vol. 159, No. 3 (Aug. 1, 1997), pp. 1383-1392.
Barry et al. “Protease inhibitors in patients with HIV disease. Clinically important pharmacokinetic considerations”, Clinical Pharmacokinetics, vol. 32, No. 3 (Mar. 1997), pp. 194-209.
Ramshaw et al. “Enhanced antibody responses to antigens presented on autologous erythrocytes”, Journal of Immunological Methods, vol. 18, Nos. 3-4,(1977) pp. 251-255. Complete reference.
Naryshkin et al. RNA recognition and regulation of HIV-1 gene expression by viral factor Tat. Biochemistry (Mosc) May, 1998 vol. 63(5), pp. 489-503. Abstract only.
Campbell et al. The C Terminus of HIV-1 Tat Modulates the Extent of CD178-mediated Apoptosis of T Cells. The Journal of Biological Chemistry. Nov. 18, 2005. vol. 280, No. 46, pp. 38376-38382.
Martinez-Picado. HIV-1 Drug Resistance Assays in Clinical Management. AIDS Clinical Care Nov. 1998, vol. 10 No. 11, pp. 81-88.
Kusumi et al. Human Immunodeficiency Virus Type 1 Envelope Gene Structure and Diversity in Vivo and after Cocultivation in Vitro. Journal of Virology, Feb. 1992, vol. 66, No. 2, pp. 875-885.
Meyerhans et al. Temporal fluctuations in HIV quasispecies in vivo are not reflected by sequential HIV isolations. Cell 1989 Sep. 8, vol. 58(5), pp. 901-910. Abstract only.
Altman et al. HIV escape: there and back again. Nature Medicine Mar. 2004, vol. 10, No. 3, pp. 229-230.
Desrosiers. Prospects for an AIDS vaccine. Nature Medicine Mar. 2004, vol. 10, No. 3, pp. 221-223.
Leslie et al. HIV evolution: CTL escape mutation and reversion after transmission. Nature Medicine Mar. 2004, vol. 10, No. 3, pp. 282-289.
Friedrich et al. Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nature Medicine Mar. 2004, vol. 10, No. 3, pp. 275-281.
Gu et al. Phase separation of acetonitrile—water mixture in protein purification. Separation Techonology, Oct. 1994, vol. 4, pp. 258-260.
Kim et al., “Introduction of Soluble Proteins into the MHC Class I Pathway by Conjugation to an HIV tat Peptide”,The Journal of Immunology, 1997, 159: 1666-1668.
Hinkula et al., “Nucleic Acid Vaccination with HIV Regulatory Genes: A Combination of HIV-1 Genes in Separate Plasmids Induces Strong Immune Responses”,Vaccine1997, vol. 15, No. 8.
Hinkula et al., “Recognition of Prominent Viral Epitopes Induced by Immunization with Human Immunodeficiency Virus Type 1 Regulatory Genes”,Journal of Virology, Jul. 1997, pp. 5528-5539.
Samaniego, “Inflammatory Cytokines Induce Endothelial Cells to Produce and Release Basic Fibroblast Growth Factor and to Promote Karposi's Sarcoma-Like Lesions in Nude Mice”,Immunology, 1997, 158: 1887-1894.
Allen et al., 2002, “Tat-Vaccinated Macaques Do Not Control Simian Immunodeficiency Virus SIVmac239 Replication,”J. Virology, 76(8): 4108-4112.
Cafaro et al., 2000, “SHIV89.6P pathogenicity in cynomolgus monkeys and control of viral replication and disease onset by human immunodeficiency virus type 1 Tat vaccine,”J, Med. Primatol., 29: 193-208.
Calarota et al., 1999, “Immune Responses in Asymptomatic HIV-1-Infected Patients After HIV-DNA Immunization Followed by Highly Active Antiretroviral Treatment,”J. Immunology, 163(4): 2330-2338.
Calarota et al., 1998, “Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients,”The Lancet, 351:1320-1325.
Fanales-Belasio et al., 2002, “HIV-1 Tat-Based Vaccines: From Basic Science to Clinical Trials,”DNA and Cell Biology, 21(9): 599-610.
Frankel et al., 1988, “Tat Protein from Human Immunodeficiency Virus Forms a Me0Otal-Linked Dimer,”Science, 240 (4848):70-73.
Johnston, Margaret, 2000, “The role of nonhuman primate models in AIDS vaccine development,”Molecular Medicine Today, 6:267-270.
Lu, Yichen, 1997, “HIV-1 Vaccine Candidate Evaluation in Non-Human Primates,”Critical Reviews in Oncogenesis, 8(2&3):273-291.
McMichael, Andrew and Rowland-Jones, Sarah, 2001, “Cellular immune responses to HIV,”Nature, 410:980-987.
Nath et al., 2000, “The chimpanzee and other non-hum

Affiliated with

Also associated with

Rating

HIV-1 Tat compositions does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HIV-1 Tat compositions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HIV-1 Tat compositions will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4167913